S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Liverpool owner FSG announces minority investment by New York equity firm
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
The Justice Department Is Suing eBay, Alleging Unlawful Sales of Over 371,000 Products
3 Reasons Micron is a Buy on Market Weakness
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Liverpool owner FSG announces minority investment by New York equity firm
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
The Justice Department Is Suing eBay, Alleging Unlawful Sales of Over 371,000 Products
3 Reasons Micron is a Buy on Market Weakness
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Liverpool owner FSG announces minority investment by New York equity firm
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
The Justice Department Is Suing eBay, Alleging Unlawful Sales of Over 371,000 Products
3 Reasons Micron is a Buy on Market Weakness
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Liverpool owner FSG announces minority investment by New York equity firm
U.S. drive to onshore battery supply chains could create big winners in lithium (Ad)
The Justice Department Is Suing eBay, Alleging Unlawful Sales of Over 371,000 Products
3 Reasons Micron is a Buy on Market Weakness
NASDAQ:ROIV

Roivant Sciences (ROIV) Stock Forecast, Price & News

$12.55
-0.64 (-4.85%)
(As of 09/28/2023 ET)
Compare
Today's Range
$12.25
$13.24
50-Day Range
$10.21
$13.19
52-Week Range
$3.14
$13.24
Volume
8.27 million shs
Average Volume
6.12 million shs
Market Capitalization
$9.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.38

Roivant Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
22.5% Upside
$15.38 Price Target
Short Interest
Healthy
3.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of Roivant Sciences in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$8.32 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.06) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

746th out of 970 stocks

Pharmaceutical Preparations Industry

356th out of 454 stocks


ROIV stock logo

About Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

ROIV Price History

ROIV Stock News Headlines

U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Roivant Sciences' (ROIV) "Buy" Rating Reiterated at Truist Financial
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Skin In The Game: Behind Roivant's Significant Rise
The Brash Strategy That Made Vivek Ramaswamy a Fortune
Roivant Sciences (NASDAQ: ROIV)
See More Headlines
Receive ROIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.

ROIV Company Calendar

Last Earnings
8/14/2023
Today
9/29/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ROIV
Fax
N/A
Employees
904
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.38
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+22.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-1,009,030,000.00
Net Margins
-1,233.11%
Pretax Margin
-1,528.46%

Debt

Sales & Book Value

Annual Sales
$61.28 million
Book Value
$2.11 per share

Miscellaneous

Free Float
736,242,000
Market Cap
$9.69 billion
Optionable
Not Optionable
Beta
1.28
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Matthew Gline (Age 39)
    CEO & Director
    Comp: $1.77M
  • Dr. Eric Venker M.D. (Age 36)
    Pharm.D., Pres & COO
    Comp: $1.28M
  • Dr. Mayukh Sukhatme M.D. (Age 47)
    Pres & Chief Investment Officer
    Comp: $1.72M
  • Mr. Richard Pulik (Age 43)
    Chief Financial Officer
  • Ms. Rakhi KumarMs. Rakhi Kumar (Age 43)
    Chief Accounting Officer
  • Dr. Huafeng Xu Ph.D.
    Chief Technology Officer
  • Mr. Josh Chen
    Gen. Counsel
  • Ms. Kelly Graff
    Head of People
  • Ms. Marianne L. Romeo (Age 55)
    Head of Global Transactions & Risk Management
  • Mr. Alex Gasner
    Exec. VP of Roivant Health













ROIV Stock - Frequently Asked Questions

Should I buy or sell Roivant Sciences stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ROIV shares.
View ROIV analyst ratings
or view top-rated stocks.

What is Roivant Sciences' stock price forecast for 2023?

8 brokerages have issued 12 month target prices for Roivant Sciences' shares. Their ROIV share price forecasts range from $10.00 to $23.00. On average, they predict the company's share price to reach $15.38 in the next year. This suggests a possible upside of 22.5% from the stock's current price.
View analysts price targets for ROIV
or view top-rated stocks among Wall Street analysts.

How have ROIV shares performed in 2023?

Roivant Sciences' stock was trading at $7.99 on January 1st, 2023. Since then, ROIV stock has increased by 57.1% and is now trading at $12.55.
View the best growth stocks for 2023 here
.

Are investors shorting Roivant Sciences?

Roivant Sciences saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 18,340,000 shares, a decrease of 13.4% from the August 31st total of 21,190,000 shares. Based on an average daily volume of 4,980,000 shares, the short-interest ratio is presently 3.7 days. Currently, 3.6% of the shares of the stock are sold short.
View Roivant Sciences' Short Interest
.

When is Roivant Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ROIV earnings forecast
.

How were Roivant Sciences' earnings last quarter?

Roivant Sciences Ltd. (NASDAQ:ROIV) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.10. The firm earned $21.60 million during the quarter, compared to the consensus estimate of $24.49 million. Roivant Sciences had a negative net margin of 1,233.11% and a negative trailing twelve-month return on equity of 73.68%. The company's revenue was up 402.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.48) earnings per share.

What is Roivant Sciences' stock symbol?

Roivant Sciences trades on the NASDAQ under the ticker symbol "ROIV."

How do I buy shares of Roivant Sciences?

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Roivant Sciences' stock price today?

One share of ROIV stock can currently be purchased for approximately $12.55.

How much money does Roivant Sciences make?

Roivant Sciences (NASDAQ:ROIV) has a market capitalization of $9.69 billion and generates $61.28 million in revenue each year. The company earns $-1,009,030,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

How many employees does Roivant Sciences have?

The company employs 904 workers across the globe.

How can I contact Roivant Sciences?

Roivant Sciences' mailing address is Clarendon House, 2 Church Street, Hamilton Parish HM 11. The official website for the company is roivant.com. The company can be reached via phone at 44-20-7400-3347.

This page (NASDAQ:ROIV) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -